Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Merit designs, manufactures, and markets disposable medical products primarily for the diagnosis and treatment of cardiovascular disease. Key product lines include inflation devices, catheters, guide wires, and custom procedure kits. The company operates manufacturing facilities in the United States (Utah, Texas, Virginia) and Ireland, with sales distributed globally.
Key Financial Metrics (Year Ended Dec 31, 2004)
| Metric | 2004 (in thousands) | 2003 (in thousands) |
|---|---|---|
| Net Sales | $151,398 | $135,953 |
| Gross Profit | $67,490 | $60,723 |
| Gross Margin | 44.6% | 44.7% |
| Net Income | $17,932 | $17,295 |
| Diluted EPS | $0.65 | $0.64 |
| Cash from Operations | $30,016 | $25,193 |
| Cash and Equivalents (Ending) | $33,037 | $30,204 |
| Working Capital | $54,944 | $56,931 |
| Long-Term Debt | $5 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.4% to $151.4 million, driven by a 16% increase in catheter sales, 11% in inflation devices, and 10% in custom kits. Unit growth was primarily due to procedural volume increases (6-8%) and market share gains.
- Profitability: Net income rose 4% to $17.9 million. Gross margin decreased slightly by 0.1% due to increased standard manufacturing costs.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 15.1% to $35.1 million. This was largely due to $674,000 in Sarbanes-Oxley compliance costs and $663,000 in severance expenses.
- Capital Expenditures: Significant investment was made in facilities, including $15.8 million spent on construction in 2004 for new manufacturing space in South Jordan, Utah, and Galway, Ireland.
- Acquisition: In November 2004, the company acquired MedSource Packaging Concepts LLC for approximately $1.46 million (cash, warrants, and assumed liabilities) to expand custom procedure tray capabilities.
Guidance, Outlook, and Risks
- Margin Outlook: Management expects gross margins to decline slightly in 2005 due to higher overhead from new facilities, the integration of lower-margin MedSource pack business, and the introduction of new products.
- Growth Strategy: The company plans to invest in additional sales representatives and expects to release new products in the second half of 2005 to drive future sales growth.
- Key Risks:
- Product Liability & Recalls: Inherent risks associated with invasive medical procedures.
- Competition: Intense competition from larger firms (e.g., Boston Scientific, Medtronic) with greater resources.
- Regulatory: Dependence on FDA approvals and compliance with Good Manufacturing Practices.
- Foreign Exchange: Approximately 10.2% of sales were denominated in Euros; fluctuations could negatively impact financial results.
- Concentration: Inflation devices accounted for 33% of total revenues in 2004.
- Accounting Changes: The company anticipates adopting SFAS No. 123R (Share-based Payment) in 2005, which will require recognizing stock-based compensation expense, potentially reducing reported net income.
Investor Verification Checklist
- Margin Compression: Verify the extent of margin decline in 2005 as the company absorbs costs from new facilities and the MedSource acquisition.
- Stock-Based Compensation Impact: Assess the potential reduction in net income upon the adoption of SFAS No. 123R in July 2005.
- Capital Expenditure Completion: Confirm the completion and operational readiness of the new South Jordan and Galway facilities to ensure capacity expansion meets demand.
- Customer Concentration: Monitor the 7% sales concentration with the single largest customer (a packer) and the 33% reliance on inflation device sales.
- Foreign Exchange Exposure: Track the Euro/USD exchange rate impact on the 25% of sales generated internationally.